Internal Medicine, Rheumatology · Langhorne, PA
NPI
1265626048
Since 2007
Specialty
Internal Medicine, Rheumatology
Code 207RR0500X
Group practices
1
Medicare group memberships
Hospitals
3
Hospital affiliations
920 Town Center Dr Ste I30
Langhorne, PA, 19047
Phone (215) 752-8680
Groups this clinician bills Medicare through
Medicare paid, 2024
$357K
31,155 services
Medicare patients, 2024
223
Average age 74
Drug cost, 2024
$2.2M
2,387 prescriptions
Company payments, 2025
$2,184
From 17 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Barry L Getzoff was code J0897 (injection, denosumab, 1 mg), 3,480 times for 36 patients. In total Barry L Getzoff billed 31,155 services in 34 codes, and Medicare paid $357K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2018-02-25.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J0897 Injection, denosumab, 1 mg | Office | 3,480 | 36 | $20.35 | $71K |
| J1745 Injection, infliximab, excludes biosimilar, 10 mg | Office | 2,297 | 16 | $25.07 | $58K |
| J1010 Injection, methylprednisolone acetate, 1 mg | Office | 993 | 39 | $0.10 | $102 |
| 99213 Office E&M - Established | Office | 391 | 203 | $71.91 | $28K |
| 20610 Joint Injection | Office | 100 | 38 | $62.80 | $6,280 |
| 96372 Injection Administration | Office | 91 | 42 | $10.20 | $928 |
| 96413 Chemotherapy Administration | Office | 83 | 38 | $89.97 | $7,468 |
| 96415 Chemotherapy Administration | Office | 48 | 20 | $20.20 | $970 |
| 20550 Musculoskeletal | Office | 24 | 12 | $36.08 | $866 |
| J1020 Injection, methylprednisolone acetate, 20 mg | Office | 23 | 11 | $3.71 | $85.22 |
| J1030 Injection, methylprednisolone acetate, 40 mg | Office | 14 | 11 | $4.32 | $60.44 |
By year: 2022 $956K for 65,944 services; 2023 $688K for 53,517 services; 2024 $357K for 31,155 services.
Medicare prescription drug claims, 2024
In 2024, the drug Barry L Getzoff prescribed most often to Medicare patients was Methotrexate (Methotrexate Sodium), with 206 prescriptions and refills. In total Barry L Getzoff wrote 2,387 Medicare prescriptions that cost $2.2M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Methotrexate Methotrexate Sodium | 206 | 512 | 52 | $6,866 |
| Tramadol Hcl Generic | 204 | 204 | 31 | $1,894 |
| Prednisone Generic | 193 | 385 | 52 | $1,505 |
| Celecoxib Generic | 179 | 335 | 35 | $6,008 |
| Gabapentin Generic | 153 | 280 | 44 | $2,127 |
| Hydroxychloroquine Sulfate Generic | 132 | 312 | 42 | $6,100 |
| Meloxicam Generic | 121 | 230 | 39 | $345 |
| Tizanidine Hcl Generic | 90 | 152 | 28 | $686 |
| Xeljanz Tofacitinib Citrate | 72 | 80 | Under 11 | $468K |
| Duloxetine Hcl Generic | 70 | 162 | 18 | $1,507 |
| Rinvoq Upadacitinib | 66 | 80 | Under 11 | $494K |
| Allopurinol Generic | 52 | 98 | Under 11 | $701 |
| Enbrel Sureclick Etanercept | 45 | 50 | Under 11 | $375K |
| Zolpidem Tartrate Generic | 43 | 53 | Under 11 | $125 |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | 42 | 43 | Under 11 | $658 |
Brand drugs: 343 claims; generic drugs: 2,044 claims; opioid claims: 285.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Barry L Getzoff $2,184 ($2,184 in general payments such as food, travel and fees) from 17 companies. The largest payer was Amgen Inc. with $380.
| Company | Payments | Amount |
|---|---|---|
| Amgen Inc. AMGN | 15 | $380 |
| AstraZeneca Pharmaceuticals LP AZN | 16 | $367 |
| ANI Pharmaceuticals, Inc. ANIP | 10 | $264 |
| Pfizer Inc. PFE | 7 | $251 |
| Abbvie Inc. ABBV | 10 | $187 |
| Janssen Biotech, Inc. JNJ | 5 | $175 |
| Novo Nordisk Inc NVO | 1 | $115 |
| E.R. Squibb & Sons, L.L.C. BMY | 5 | $98.91 |
| Novartis Pharmaceuticals Corporation NVS | 4 | $92.77 |
| GlaxoSmithKline, LLC. GSK | 3 | $54.57 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.